Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel adenovirus

Inactive Publication Date: 2018-08-02
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a recombinant adenovirus that encodes a mycobacterial antigen and can be used as a medicament to stimulate the immune system against mycobacterial infection. The recombinant adenovirus has been found to be safe and effective in animal models. The technical effect of this invention is to provide an improved method for treating mycobacterial infections.

Problems solved by technology

It is a major disease in developing countries, as well as an increasing problem in developed areas of the world.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel adenovirus
  • Novel adenovirus
  • Novel adenovirus

Examples

Experimental program
Comparison scheme
Effect test

example 1

of ChAd155

[0376]Wild type chimpanzee adenovirus type 155 (ChAd155) was isolated from a healthy young chimpanzee housed at the New Iberia Research Center facility (New Iberia Research Center; The University of Louisiana at Lafayette) using standard procedures as described in Colloca et al. (2012) and WO2010086189, which is hereby incorporated by reference for the purpose of describing adenoviral isolation and characterization techniques

example 2

ector Construction

[0377]The ChAd155 viral genome was then cloned in a plasmid or in a BAC vector and subsequently modified (FIG. 2) to carry the following modifications in different regions of the ChAd155 viral genome:

a) deletion of the E1 region (from bp 449 to bp 3529) of the viral genome;

b) deletion of the E4 region (from bp 34731 to bp 37449) of the viral genome;

c) insertion of the E4orf6 derived from human Ad5.

2.1: Deletion of E1 Region: Construction of BAC / ChAd155 ΔE1 TetO hCMV RpsL-Kana#1375

[0378]The ChAd155 viral genome was cloned into a BAC vector by homologous recombination in E. coli strain BJ5183 electroporation competent cells (Stratagene catalog no. 2000154) co-transformed with ChAd155 viral DNA and Subgroup C BAC Shuttle (#1365). As shown in the schematic of FIG. 3, the Subgroup C Shuttle is a BAC vector derived from pBeloBAC11 (GenBank U51113, NEB) and which is dedicated to the cloning of ChAd belonging to species C and therefore contains the pIX gene and DNA fragmen...

example 3

oduction

[0395]The productivity of ChAd155 was evaluated in comparison to ChAd3 and PanAd3 in the Procell 92 cell line.

3.1: Production of Vectors Comprising an HIV Gag Transgene

[0396]Vectors expressing the HIV Gag protein were prepared as described above (ChAd155 / GAG) or previously (ChAd3 / GAG Colloca et al, Sci. Transl. Med. (2012) 4:115ra). ChAd3 / GAG and ChAd155 / GAG were rescued and amplified in Procell 92 until passages 3 (P3); P3 lysates were used to infect 2 T75 flasks of Procell 92 cultivated in monolayer with each vector. A multiplicity of infection (MOI) of 100 vp / cell was used for both infection experiments. The infected cells were harvested when full CPE was evident (72 hours post-infection) and pooled; the viruses were released from the infected cells by 3 cycles of freeze / thaw (−70° / 37° C.) then the lysate was clarified by centrifugation. The clarified lysates were quantified by Quantitative PCR Analysis with primers and probe complementary to the CMV promoter region. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
serologic cross reactivityaaaaaaaaaa
weight lossaaaaaaaaaa
Login to View More

Abstract

There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

Description

FIELD OF THE INVENTION[0001]The present invention relates to adenoviral vectors encoding a mycobacterial antigen, more particular to adenoviral vectors derived from chimp adenovirus ChAd155, and to related aspects.BACKGROUND OF THE INVENTION[0002]Tuberculosis (TB) is a chronic infectious disease caused by infection with Mycobacterium tuberculosis and other Mycobacterium species. It is a major disease in developing countries, as well as an increasing problem in developed areas of the world.[0003]Vaccination is one of the most effective methods for preventing or treating infectious diseases. Adenovirus has been widely used for gene transfer applications due to its ability to achieve highly efficient gene transfer in a variety of target tissues and large transgene capacity. Conventionally, E1 genes of adenovirus are deleted and replaced with a transgene cassette consisting of the promoter of choice, cDNA sequence of the gene of interest and a poly A signal, resulting in a replication d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N7/00C12N15/86C07K14/005A61K35/761C07K14/35A61K39/04A61P31/06
CPCC12N7/00C12N15/86C07K14/005A61K35/761C07K14/35A61K39/04A61P31/06A61K2039/5256C12N2710/10321C12N2710/10343C12N2710/10341A61K2039/545A61K39/12C12N2740/16234C12N2760/18534A61K39/235A61K9/0019A61K39/39A61K45/05C12N15/85
Inventor COLLOCA, STEFANOAMMENDOLA, VIRGINIAGRAZIOLI, FABIANAVITELLI, ALESSANDRANICOSIA, ALFREDOCORTESE, RICCARDO
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com